The current investigation demonstrates the potential of the designed templates OAcSGP+CD10+CD19+ or OAcSGP+CD34+CD19+ or OAcSGP+CD7+CD3+ for successful diagnosis and evaluation of the disease status during the two-year chemotherapy, suggesting its application in MRD detection and prediction of impending relapse in ALL both in PB and BM. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.